Inflammation in psychotic disorders: A population-based study

Psychiatry Research

Volumn 189, Issue 2, 2011, Pages 305-311

  Suvisaari, Jaana ^a,b   Loo, Britt Marie ^a   Saarni, Suoma E ^a   Haukka, Jari ^a,c   Perälä, Jonna ^a   Saarni, Samuli I ^a,c   Viertiö, Satu ^a   Partti, Krista ^a   Lönnqvist, Jouko ^a,c   Jula, Antti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antipsychotic medication; Cytokines; Inflammation; Psychotic disorders; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AFFECTIVE PSYCHOSIS; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD; PHAGOCYTOSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SMOKING HABIT; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; COMMUNITY HEALTH PLANNING; COMORBIDITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LINEAR MODELS; LIPIDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 80052791934     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.07.006     Document Type: Article

References (52)

1. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute 2004, B12. Available in English at, Accessed December 12, 2010. http://www.terveys2000.fi/julkaisut/baseline.pdf, A. Aromaa, S. Koskinen (Eds.).
2. Bauer S. Cytokine control of adult neural stem cells. Chronic versus acute exposure. Annals of the New York Academy of Science 2009, 1153:48-56.
3. Berthold-Losleben M., Himmerich H. The TNF-α system: functional aspects in depression, narcolepsy, and psychopharmacology. Current Neuropharmacology 2008, 6:193-202.
4. Bøttcher S.G. Learning Bayesian networks with mixed variables. Artificial Intelligence and Statistics 2001, 149-156. Morgan Kaufmann, San Francisco, CA, USA.
5. Bøttcher S.G., Dethlefsen C. DEAL: a package for learning Bayesian networks. Journal of Statistical Software 2003, 8(20). Available at. http://www.jstatsoft.org/v08/i20/paper.
6. Brietzke E., Stertz L., Fernandes B., Kauer-Sant'Anna M., Mascarenhas M., Escosteguy Vargas A., Chies J.A., Kapczinski F. Comparison of cytokine levels in depressed, manic, and euthymic patients with bipolar disorder. Journal of Affective Disorders 2009, 116:214-217.
7. Carrizo E., Fernández V., Quintero J., Connell L., Rodríguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophrenia Research 2008, 103:83-93.
8. Carstensen M., Herder C., Kivimäki M., Jokela M., Roden M., Shipley M.J., Witte D.R., Brunner E.J., Tabák A.G. Accelerated increase in serum interleukin-1 receptor antagonist starts 6years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010, 59:1222-1227.
9. Cartier A., Bergeron J., Poirier P., Almeras N., Tremblay A., Lemieux I., Despres J.P. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Annals of Medicine 2009, 41:471-478.
10. Cook R.T. Alcohol abuse, alcoholism, and damage to the immune system - a review. Alcoholism, Clinical and Experimental Research 1998, 22:1927-1942.
11. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9:46-57.
12. de Araujo E.G., da Silva G.M., Dos Santos A.A. Neuronal cell survival: the role of interleukins. Annals of the New York Academy of Science 2009, 1153:57-64.
13. Drexhage R.C., Knijff E.M., Padmos R.C., van der Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics 2010, 10:59-76.
14. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disorders 2010, 12:638-646.
15. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
16. Fearon W.F., Fearon D.T. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 2008, 117:2577-2579.
17. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. The British Journal of Psychiatry 2009, 194:434-438.
18. Ganguli R., Brar J.S., Rabin B.S. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harvard Review of Psychiatry 1994, 2:70-83.
19. Hajer G.R., van Haeften T.W., Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular disease. European Heart Journal 2008, 29:2959-2971.
20. Methodology report. Health 2000 Survey. Publications of the National Public Health Institute 2008, B26. Available in English at, Accessed December 12, 2010. http://www.terveys2000.fi/doc/methodologyrep.pdf, S. Heistaro (Ed.).
21. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., Agartz I., Ueland T., Andreassen O.A. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorders 2009, 11:726-734.
22. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S., Uchitomi Y. Plasma concentrations of interleukin-1β, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor-α of depressed patients in Japan. Neuropsychobiology 2001, 43:59-62.
23. Katila H., Hänninen K., Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Molecular Psychiatry 1999, 4:179-181.
24. Kim S.J., Lee H.J., Koo H.G., Kim J.W., Song J.Y., Kim M.K., Shin D.H., Jin S.Y., Hong M.S., Park H.J., Yoon S.H., Park H.K., Chung J.H. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatric Genetics 2004, 14:165-167.
25. Lakoski S.G., Cushman M., Palmas W., Blumenthal R., D'Agostino R.B., Herrington D.M. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). Journal of the American College of Cardiology 2005, 46:1869-1874.
26. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehse J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine 2007, 356:1517-1526.
27. Lim L.S., Haq N., Mahmood S., Hoeksema L., ACPM Prevention Practice Committee Atherosclerotic cardiovascular disease screening in adults: American College Of Preventive Medicine position statement on preventive practice. American Journal of Preventive Medicine 2011, 40(381):e1-e10.
28. Luotola K., Pietilä A., Alanne M., Lanki T., Loo B.M., Jula A., Perola M., Peters A., Zeller T., Blankenberg S., Salomaa V., Health 2000, FINRISK97, and AIRGENE Study Groups Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes. Metabolism 2010, 59:1520-1527.
29. Luotola K., Pietilä A., Zeller T., Moilanen L., Kähönen M., Nieminen M.S., Kesäniemi Y.A., Blankenberg S., Jula A., Perola M., Salomaa V., Health 2000 and FINRISK97 Studies Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. Journal of Internal Medicine 2011, 269:322-332.
30. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Progress in Neuro-Psychopharmacology and Biological 2010, Psychiatry [Epub ahead of print].
31. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nature Reviews Immunology 2004, 4:665-674.
32. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry 2009, 66:1013-1022.
33. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009, 65:732-741.
34. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine 2008, 14:109-119.
35. Perälä J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsä E., Pirkola S., Partonen T., Tuulio-Henriksson A., Hintikka J., Kieseppä T., Härkänen T., Koskinen S., Lönnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007, 64:19-28.
36. Piccirillo C.A. Regulatory T cells in health and disease. Cytokine 2008, 43:395-401.
37. Pop V.J., Maartens L.H., Leusink G., van Son M.J., Knottnerus A.A., Ward A.M., Metcalfe R., Weetman A.P. Are autoimmune thyroid dysfunction and depression related?. The Journal of Clinical Endocrinology & Metabolism 1998, 83:3194-3197.
38. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
39. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes. JAMA 2001, 286:327-334.
40. R Development Core Team R: A language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna, Austria, URL http://www.R-project.org.
41. Rapaport M.H., Torrey E.F., McAllister C.G., Nelson D.L., Pickar D., Paul S.M. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. European Archives of Psychiatry and Clinical Neuroscience 1993, 243:7-10.
42. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., Macfadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182. JUPITER Trial Study Group.
43. Ruiz J.R., Ortega F.B., Wärnberg J., Moreno L.A., Carrero J.J., Gonzalez-Gross M., Marcos A., Gutierrez A., Sjöström M. Inflammatory proteins and muscle strength in adolescents. The AVENA study. Archives of Pediatrics & Adolescent Medicine 2008, 162:462-468.
44. Saarni S.E., Saarni S.I., Fogelholm M., Heliövaara M., Perälä J., Suvisaari J., Lönnqvist J. Body composition in psychotic disorders - a general population survey. Psychological Medicine 2009, 39:801-810.
45. Schrager M.A., Metter E.J., Simonsick E., Ble A., Bandinelli S., Lauretani F., Ferrucci L. Sarcopenic obesity and inflammation in the InCHIANTI study. Journal of Applied Physiology 2007, 102:919-925.
46. Sopori M. Effects of cigarette smoke on the immune system. Nature Reviews Immunology 2002, 2:372-377.
47. Suvisaari J.M., Saarni S.I., Perälä J., Suvisaari J.V.J., Härkänen T., Lönnqvist J., Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. The Journal of Clinical Psychiatry 2007, 68:1045-1055.
48. Suvisaari J., Perälä J., Saarni S.I., Härkänen T., Pirkola S., Joukamaa M., Lönnqvist J., Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:129-136.
49. Suvisaari J., Perälä J., Saarni S.I., Juvonen H., Tuulio-Henriksson A., Lönnqvist J. The epidemiology and descriptive and predictive validity of DSM-IV delusional disorder and subtypes of schizophrenia. Clinical Schizophrenia & Related Psychoses 2009, 2:289-297.
50. Tsai S.-Y., Chen K.-P., Yang Y.-Y., Chen C.-C., Lee J.-C., Singh V.K., Leu S.-J.C. Activation of indices of cell-mediated immunity in bipolar mania. Biological Psychiatry 1999, 45:989-994.
51. Vonk R., van der Schot A.C., Kahn R.S., Nolen W.A., Drexhage H.A. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder?. Biological Psychiatry 2007, 62:135-140.
52. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nature Reviews Genetics 2009, 10:43-55.